MXPA04007328A - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MXPA04007328A MXPA04007328A MXPA04007328A MXPA04007328A MXPA04007328A MX PA04007328 A MXPA04007328 A MX PA04007328A MX PA04007328 A MXPA04007328 A MX PA04007328A MX PA04007328 A MXPA04007328 A MX PA04007328A MX PA04007328 A MXPA04007328 A MX PA04007328A
- Authority
- MX
- Mexico
- Prior art keywords
- propofol
- pharmaceutical composition
- cyclodextrin
- freeze
- solution
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200200929 | 2002-02-01 | ||
| US40163302P | 2002-08-06 | 2002-08-06 | |
| PCT/IB2003/000266 WO2003063824A2 (en) | 2002-02-01 | 2003-01-29 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007328A true MXPA04007328A (es) | 2005-07-05 |
Family
ID=27669352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007328A MXPA04007328A (es) | 2002-02-01 | 2003-01-29 | Composicion farmaceutica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050239746A1 (enExample) |
| EP (1) | EP1469886B8 (enExample) |
| JP (1) | JP2005522422A (enExample) |
| CN (1) | CN1625414A (enExample) |
| AT (1) | ATE326985T1 (enExample) |
| AU (1) | AU2003205930B2 (enExample) |
| BR (1) | BR0307518A (enExample) |
| CA (1) | CA2474710A1 (enExample) |
| DE (1) | DE60305438T2 (enExample) |
| MX (1) | MXPA04007328A (enExample) |
| NZ (1) | NZ534598A (enExample) |
| WO (1) | WO2003063824A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1574221T3 (da) * | 2004-03-10 | 2007-07-16 | Shimoda Biotech Pty Ltd | Stabile, injicérbare diclofenacsammensætninger |
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| JPWO2006112276A1 (ja) | 2005-04-13 | 2008-12-11 | 株式会社大塚製薬工場 | プロポフォール含有脂肪乳剤 |
| JP2009504634A (ja) * | 2005-08-12 | 2009-02-05 | ブハラット セルムズ アンド ヴァクシンズ リミテッド | プロポフォールを含む水性麻酔剤組成物 |
| BRPI0709409A2 (pt) | 2006-03-28 | 2011-07-12 | Javelin Pharmaceuticals Inc | composição farmacêutica e método para tratar um mamìfero necessitando de analgesia |
| EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
| EP2484350B1 (de) * | 2011-02-04 | 2016-04-20 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin |
| SG11201401597TA (en) | 2011-11-29 | 2014-05-29 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| CN103172658B (zh) * | 2011-12-26 | 2016-01-20 | 宜昌人福药业有限责任公司 | 一种适合药用的前体药物晶型、制备方法及药用组合物 |
| CN104870001B (zh) | 2012-11-15 | 2019-01-18 | 赛博尔泰克股份公司 | 用作消炎或免疫抑制有效成分的飞燕草素络合物 |
| HK1215392A1 (zh) | 2012-12-11 | 2016-08-26 | 赛博尔泰克股份公司 | 用於对抗黑色素瘤细胞的飞燕草素 |
| EP2913050A1 (de) * | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Verfahren zur Herstellung eines Flurankomplexes |
| CN104523591B (zh) * | 2014-12-19 | 2019-01-18 | 西安力邦肇新生物科技有限公司 | 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法 |
| CN111529695A (zh) * | 2020-04-30 | 2020-08-14 | 首都医科大学附属北京康复医院（北京工人疗养院） | 一种环糊精可溶性ace2及其制备方法和应用 |
| KR20220057901A (ko) * | 2020-10-30 | 2022-05-09 | 현대자동차주식회사 | 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법 |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
| WO2023156970A1 (en) * | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA828580B (en) * | 1981-12-23 | 1983-10-26 | Schering Corp | Interferon formulations |
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
| WO1996041646A2 (en) * | 1995-06-13 | 1996-12-27 | Dyer, Alison, Margaret | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
| NZ331509A (en) * | 1996-02-19 | 2000-04-28 | Nycomed Imaging As | Aqueous dispersions of stabilised gas microbubbles and their use as contrast agents |
| US6407278B2 (en) * | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| EP1244444B1 (en) * | 1999-10-29 | 2004-12-29 | Merck & Co., Inc. | Process for formulation of carbapenem antibiotic compositions |
| IN187686B (enExample) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
| WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
-
2003
- 2003-01-29 DE DE60305438T patent/DE60305438T2/de not_active Expired - Lifetime
- 2003-01-29 JP JP2003563518A patent/JP2005522422A/ja active Pending
- 2003-01-29 NZ NZ534598A patent/NZ534598A/en not_active IP Right Cessation
- 2003-01-29 EP EP03702813A patent/EP1469886B8/en not_active Expired - Lifetime
- 2003-01-29 BR BR0307518-4A patent/BR0307518A/pt not_active IP Right Cessation
- 2003-01-29 AU AU2003205930A patent/AU2003205930B2/en not_active Ceased
- 2003-01-29 AT AT03702813T patent/ATE326985T1/de not_active IP Right Cessation
- 2003-01-29 CA CA002474710A patent/CA2474710A1/en not_active Abandoned
- 2003-01-29 CN CNA038031442A patent/CN1625414A/zh active Pending
- 2003-01-29 WO PCT/IB2003/000266 patent/WO2003063824A2/en not_active Ceased
- 2003-01-29 US US10/503,067 patent/US20050239746A1/en not_active Abandoned
- 2003-01-29 MX MXPA04007328A patent/MXPA04007328A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050239746A1 (en) | 2005-10-27 |
| ATE326985T1 (de) | 2006-06-15 |
| CA2474710A1 (en) | 2003-08-07 |
| AU2003205930B2 (en) | 2007-08-16 |
| DE60305438D1 (de) | 2006-06-29 |
| EP1469886B1 (en) | 2006-05-24 |
| WO2003063824A2 (en) | 2003-08-07 |
| DE60305438T2 (de) | 2006-12-21 |
| BR0307518A (pt) | 2004-12-28 |
| NZ534598A (en) | 2004-11-26 |
| EP1469886B8 (en) | 2008-01-09 |
| EP1469886A2 (en) | 2004-10-27 |
| WO2003063824A3 (en) | 2004-06-17 |
| CN1625414A (zh) | 2005-06-08 |
| JP2005522422A (ja) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003205930B2 (en) | Pharmaceutical composition | |
| AU2003205930A1 (en) | Pharmaceutical composition | |
| US7678776B2 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| KR100349754B1 (ko) | 제약조성물 | |
| KR20080028289A (ko) | 수 난용성 캄토테신 유도체의 미세 나노입자 및 그의제조방법 | |
| WO1996032135A1 (en) | Pharmaceutical composition | |
| US6077871A (en) | Droloxifene pharmaceutical compositions | |
| WO1996041646A2 (en) | Pharmaceutical compositions containing lornoxicam and cyclodextrin | |
| AU777684B2 (en) | Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins | |
| EP2035040B1 (en) | Pharmaceutical composition for administration by injection | |
| CA2486571C (en) | Pharmaceutical composition | |
| ZA200406021B (en) | Pharmaceutical composition | |
| KR20040091004A (ko) | 약제학적 조성물 | |
| CA2017156A1 (en) | Preparation of fr115224 substance for parenteral administration | |
| AU777763B2 (en) | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties | |
| KR20100126059A (ko) | 도세탁셀을 포함하는 약학 조성물 | |
| JPH07316065A (ja) | Ｆｒ９０１４６９物質製剤 | |
| CN106727363B (zh) | 核苷氨基磷酸酯类前药的冻干形式的药物组合物 | |
| EP4482463A1 (en) | Solid and oral etoposide toniribate compositions | |
| CN110327469A (zh) | 一种乙氧苯柳胺包合物的制备方法 | |
| CN118845675A (zh) | 一种人参皂苷Rk3脂质纳米颗粒缓释制剂的制备方法 | |
| KREÄZJ et al. | The Influence of ß-Cyclodextrins on the Solubility ef-Furosemide— |